A naukri.com initiative
Alleywatch
18h
221
Inductive Bio Secures $25M Series A to Transform Drug Discovery with its Collaborative AI Platform
- Inductive Bio has raised $25M in Series A funding led by Obvious Ventures with participation from various investors to transform drug discovery with its collaborative AI platform.
- The company's AI platform accelerates compound optimization by predicting how molecules will behave in the human body before synthesis, reducing time and costs in drug development.
- Inductive Bio's pre-competitive data consortium allows multiple pharmaceutical companies to share anonymized data, enhancing AI models' learning process.
- The platform helps chemists design molecules efficiently, predicting critical ADMET properties for drug effectiveness in the human body.
- Founded by Josh Haimson and Ben Birnbaum, Inductive Bio aims to address challenges in the drug development process by using AI to expedite molecule selection.
- The company's collaborative approach, similar to Waze for drug discovery, ensures shared data from multiple companies to enhance navigation in developing therapeutics.
- Inductive Bio targets biotech and pharmaceutical companies working on small-molecule drugs across various disease areas, focusing on improving efficiency in drug development.
- The company generates revenue through software licensing and scientific collaborations, offering partners access to its AI platform for designing better drugs faster.
- Inductive Bio's technology reduces risk in drug development, making it appealing for companies looking to develop drugs more efficiently, especially in uncertain economic times.
- The company's future plans include team expansion, enhancing AI capabilities, and growing the consortium to provide more powerful predictions for partners.
Read Full Article
13 Likes
For uninterrupted reading, download the app